SUMMARY Molecular biology has made tremendous strides over the last five years. The new biology allows us to prepare monoclonal antibodies to defined antigens; to detect, isolate and clone specific genes; and to insert these genes into defined sites in different cells giving new functions to old organisms. These revolutionary developments have been followed closely by researchers, businessmen, politicians and philosophers, as well as by those involved in the clinical care of patients. Although our understanding of human molecular biology is increasing rapidly, it is the development of monoclonal antibodies that has the most immediate application in the clinic. There have been several reports of their use in the diagnosis, localisation and treatment of human malignant disease. This review describes developments that are likely to have direct relevance to patient care in the near future. 
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What is a monoclonal antibody?
The immunological response to any foreign antigen is polyclonal: many different clones of B lymphocytes are stimulated to produce antibodies. These antibodies have different molecular structures and in turn recognise different molecular conformation patterns on the stimulating antigen-the antigenic determinants. It is this complexity of antibody response that makes the antigen-antibody interaction difficult to analyse at a molecular level. This is particularly so with complex antigens such as the tumour cell surface. Monoclonal antibodies occur naturally in patients with myeloma. Here neoplastic transformation occurs in a clone of B lymphocytes with the result that large quantities of identical immunoglobulin molecules are produced. It was by using myelomas that the chemical structure of the immunoglobulin molecule was discovered.' However, the antigens to which most myeloma immunoglobulins are directed are usually unknown and are unlikely to be important. In 1975 Kohler and Milstein2 constructed a hybrid myeloma (hybridoma) which produced a monoclonal antibody directed against a specified antigen. Mice were immunised with the antigen (sheep red cells) and their spleen lymphocytes collected. The lymphocytes were fused with an established myeloma line and hybrids selected by growth in selective tissue culture medium.
Accepted for publication 18 November 1981
The resultant hybrids were rapidly growing (a property conferred by the myeloma) and yet contained new immunoglobulin genes (from the lymphocytes of the immunised mouse). The hybridomas were cloned by diluting the cells and growing up colonies from single cells. These cloned hybridomas now contained only one set of new immunoglobulin genes (Fig. 1 selection mechanism to enable the parent myeloma to be killed in the hybridoma mixture. Once established, human-human hybrids show no apparent preferential loss of chromosomes and thus the stability of the hybrid is assured. The quantity of immunoglobulin secreted by these human-human hybrids is usually of the order of 1 ug/ml which is one tenth of the output of the corresponding mouse hybridoma system. There are several advantages in using human lymphocytes to produce monoclonal antibodies. The spectrum of the human immune response which serologically defines tumour-specific antigens can be examined. There In the production of human monoclonal antibodies immunisation is not possible and the choice lies in the source of lymphocytes for fusion. There is as yet no evidence to suggest that any particular source of lymphocytes-peripheral blood, spleen, lymph node or intratumour-results in a higher frequency of the required antibodies.
SCREENING METHODS
The production of antibodies against human tumour cell surfaces requires the screening of many fusion products to find suitable immunoglobulins. Several strategies have been developed. The commonest method is to immunise mice with a chosen tumour cell line, for example a melanoma. The fusion products are screened on that melanoma in an indirect binding radioimmunoassay (see Fig. 2 ) and the activity of any positive supernatants determined on other melanomas as well as on cell lines of different types, both normal and malignant (Fig. 3) . In this way the specificity of the monoclonal antibody is characterised and its ability to distinguish tumour cells from their normal counterparts is determined.
Screening can also be performed using primary tumour material. Membrane preparations of tumours can be used to immunise rodents; the same membrane preparation can be bound to plastic wells and used in a solid phase radioimmunoassay to screen the activity of resulting monoclonal antibodies. A variant of this screening procedure is to use Colorectal cancer is a common problem in clinical oncology. Diagnosis is often difficult, requiring extensive endoscopic or radiological investigation. The assessment of recurrent disease following primary surgery is usually impossible until large masses of neoplastic tissue have accumulated. For the last 15 years much effort has been spent investigating carcinoembryonic antigen (CEA), an antigen detected by an antiserum produced in rabbits after immunisation with extracts from colonic cancer. This antigen, a glycoprotein with a molecular weight of 180 000, is found in several gastrointestinal tumours, some lung and breast tumours as well as in normal fetal colon. 15 Considerable interest has been aroused in the possibility that the measurement of CEA in the blood would relate to the tumour load in an individual patient, thus producing both a diagnostic test and a marker for monitoring progress of the disease. A major problem in the use of CEA for these purposes has been the extensive crossreaction between CEA and a variety of similar glycoproteins such an non-specific cross-reacting antigens (NCA), biliary glycoprotein (BGP) and a glycoprotein found in washings of normal colon (NCW). These glycoproteins share antigenic determinants with CEA and therefore confuse the serological analysis since different immunisation and absorption protocols result in the production of different antibodies in the resulting antiserum. Monoclonal antibodies give more precise information about the interrelations between these cell surface components and thus lead to more selective and sensitive assays for truly tumour-related products.
Several groups have now produced monoclonal antibodies to either CEA or other antigens present on colorectal carcinomas. So far these attempts have been carried out by immunising mice with either purified CEA preparations or colorectal carcinoma cell lines. After fusion, screening on either CEA or the immunising cell line has been used to identify interesting supernatants. Accolla and his colleagues16 raised 400 hybrids from mice immunised with purified CEA and found two which secreted antibodies reacting specifically with two different antigenic determinants present on CEA molecules. The affinities of these antibodies are relatively high and could be used to characterise solubilised CEA immunochemically. Herlyn et al17 immunised mice with cells grown in vitro. The screening assays included radioimmunoassay, mixed haemabsorption assays and immunofluorescence on the immunising cell line. Two hybridomas were found which secreted antibodies binding specifically to human colorectal carcinomas, either growing in culture or obtained directly from patients. These antibodies do not bind to normal colonic mucosa, to other malignant cells or to CEA.
MELANOMA
Melanoma is a tumour studied frequently by immunologists. Serology, using panels of patient sera and melanoma cells, has been used to construct large serological matrices. The biochemical separation of thedifferent serologicallyrecognisedantigens has been hampered by the low titres of the sera. There are several monoclonal antibodies against a variety of human melanoma antigens. Some of these antibodies are directed against the human DR (HLA D locus-related) antigen. In one study,18 three out of six hybridoma secreted antibodies were found to bind to the majority of melanoma cell lines and to astrocytomas, as well as to all normal and Epstein-Barr virus-transformed lymphocytes tested (the same distribution as the DR antigen). Two of the remaining antibodies, however, were found to detect two different antigens common to melanoma and astrocytoma cells only. The most elegant analysis of the use of monoclonal antibodies in characterising antigenic systems on the surface of human tumours comes from the work of Dippold and his collaborators. 19 The use of radiolabelled polyclonal antitumour antibodies for tumour detection has been attempted with limited success. The major problems have been the lack of a suitable antibody giving sufficient target to non-target contrast for imaging and also the difficulty in reproducibility preparing and purifying antitumour antibodies. The development of monoclonal antibodies has several advantages. Firstly, their defined specificity may allow the contrast required for effective imaging and, secondly, their production is reproducible on a large scale.
Furthermore, they represent a concentrated form of immunoglobulin with defined activity and thus the total foreign protein load given to an individual patient is much lower. It has been shown that mouse monoclonal antibodies to CEA and to teratocarcinomas can localise human tumour deposits in immunosuppressed mice bearing human tumour xenografts. 26 27 There are as yet, however, few reports on the use of labelled monoclonal antibodies for localisation in man. Mach and his colleagues28 injected 14 patients with large bowel and pancreatic cancer with l31I-labelled purified mouse monoclonal anti-CEA antibody. In eight patients increased radioactivity was observed in the region of the known tumour deposit. To detect blood pool and secreted radioactivity a 99mTechnetium scan was also performed. After subtraction of 99mTc radioactivity from 131I radioactivity a two to tenfold concentration of 131I activity was found in the tumour sites.
TREATMENT
Monoclonal antibodies are currently being used by several groups in attempts to assess their value as therapeutic agents. A T cell specific murine hybridoma monoclonal antibody has been infused into patients with T cell neoplasms.29 The antibody used reacts with normal human T cell differentiation antigens which are present in increased amounts on the malignant cells of patients with cutaneous T cell lymphomas. Favourable but temporary responses were seen in patients with T cell leukaemias and with mycosis fungoides, a neoplasm of T helper lymphocytes. In another study30 a mouse monoclonal antibody directed against a lymphoma-associated antigen was given to a patient with lymphosarcoma cell leukaemia. Transient decreases in circulating tumour cells and the appearance of dead cells were noted after the infusion of 75 mg of antibody. The patient had received extensive prior radiation therapy and chemotherapy. There are several mechanisms by which this tumour cell destruction can occur. These include the activation of complement; the triggering of antibody-dependent cell-mediated cytotoxicity; and opsonisation resulting in macrophage killing. It is probable that such mechanisms alone are unlikely to destroy large tumour masses but could deal effectively with well vascularised micrometastases.
Human tumours growing in immune-deprived mice have been commonly used targets for therapeutic experiments. By using anticolon carcinoma antibodies Herlyn et al31 showed that the growth rate of human colon tumours in these animals was considerably reduced. A colorectal carcinoma specific monoclonal antibody has been used to explore the possibility of coupling diptheria and ricin toxins to produce specific cytotoxic molecules.32 These toxins can be separated into two functionally distinct chains, the A active chain and the B binding chain. The A chains are specific inactivators of protein synthesis within the cell whilst the B chains are responsible for the binding of toxin molecules to receptors on cell surfaces. The A chains can be separated and coupled by conventional cross-linking agents to the antitumour monoclonal antibody. Such conjugates were shown to be cytotoxic in vitro for colorectal carcinoma cells but not toxic in the same concentration range for a variety of other human tumour and normal cell lines. The concept of using the antibody to provide the specificity of delivery and the toxin as a warhead clearly promises interesting therapeutic possibilities for the future.
